Tarsus Pharmaceuticals Acquires iRenix Medical and Adds IRX-101 to Pipeline
Tarsus Pharmaceuticals has completed its acquisition of iRenix Medical for $75 million upfront, with potential additional payments up to $490 million in milestones and royalties. The deal adds IRX-101, a late-stage investigational antiseptic targeting the retina market, which could significantly expand Tarsus' presence beyond core eye care.
Topics: Eye Care Pharmaceuticals Retina Market